Magnetic resonance imaging defines cervicovaginal anatomy, cancer, and VEGF trap antiangiogenic efficacy in estrogen-treated K14-HPV16 transgenic mice

Cancer Research

Volumn 69, Issue 20, 2009, Pages 7945-7952

  Garbow, Joel R ^a,c   Santeford, Andrea C ^b   Anderson, Jeff R ^b   Engelbach, John A ^a   Arbeit, Jeffrey M ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ESTRADIOL; GADODIAMIDE;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TRANSGENIC MOUSE; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; CAPILLARY PERMEABILITY; CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; ESTROGENS; FEMALE; GENITALIA, FEMALE; HUMANS; KERATIN-14; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350635819     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1271     Document Type: Article

References (40)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet (N Am Ed) 2007;370:890-907.
2. Marshall K. Cervical dysplasia: early intervention. Altern Med Rev 2003;8:156-170
3. Pahler JC, Tazzyman S, Erez N, et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia (NY) 2008;10:329-340
4. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008;5:e19.
5. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med 2007;13:287-297 (Pubitemid 47017002)
6. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007;6:711-724
7. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. In press 2009.
8. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging 2007;26:235-249
9. Jackson A, O'Connor JP, Parker GJ, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007;13:3449-3459 (Pubitemid 46955104)
10. Jackson A, Buckley DL, Parker GJM, editors. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer; 2005.
11. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002;47:601-606
12. Yankeelov TE, Rooney WD, Li X, Springer CS, Jr. Variation of the relaxographic "shutter-speed" for transcytolemmal water exchange affects the CR bolus-tracking curve shape. Magn Reson Med 2003;50:1151-1169
13. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000;60:1267-1275 (Pubitemid 30151994)
14. Giraudo E, Inoue M, Hanahan D. An aminobisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Investig 2004;114:623-633 (Pubitemid 39578752)
15. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862-4871 (Pubitemid 37022618)
16. Rudge JS, Thurston G, Davis S, et al. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. Cold Spring Harbor Symp Quant Biol 2005;70:411-418 (Pubitemid 44124896)
17. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 2007;67:1526-1537 (Pubitemid 46467151)
18. Garbow JR, Zhang Z, You M. Detection of primary lung tumors in rodents by magnetic resonance imaging. Cancer Res 2004;64:2740-2742 (Pubitemid 38500610)
19. Christensen KA, Grant DM, Shulman EM, Walling C. Optimal determination of relaxation times of Fourier transform nuclear magnetic resonance. Determination of spin-lattice relaxation times in chemically polarized species. J Phys Chem 1974;78:1971-1977
20. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987;5:201-208
21. Buckley DL, Shurrab AE, Cheung CM, Jones AP, Mamtora H, Kalra PA. Measurement of single kidney function using dynamic contrast-enhanced MRI: comparison of two models in human subjects. J Magn Reson Imaging 2006;24:1117-1123 (Pubitemid 44658250)
22. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232
23. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPAMR imaging. J Magn Reson Imaging 1997;7:91-101.
24. de Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004;230:652-659
25. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984;11:425-448
26. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investig Radiol 2005;40:715-724 (Pubitemid 41546838)
27. Parker GJ, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006;56:993-1000. (Pubitemid 44691341)
28. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14:457-463 (Pubitemid 32906564)
29. Kovar DA, Lewis M, Karczmar GS. A new method for imaging perfusion and contrast extraction fraction: input functions derived from reference tissues. J Magn Reson Imaging 1998;8:1126-1134 (Pubitemid 28481800)
30. Yankeelov TE, Luci JJ, Lepage M, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005;23:519-529 (Pubitemid 40779238)
31. Faranesh AZ, Kraitchman DL, McVeigh ER. Measurement of kinetic parameters in skeletal muscle by magnetic resonance imaging with an intravascular agent. Magn Reson Med 2006;55:1114-1123
32. Golub GH, Pereya V. Separable nonlinear least squares: the variable projection method and its applications. Inverse Probl 2003;19:R1-26.
33. Smith-McCune K, Zhu YH, Hanahan D, Arbeit J. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-16 transgenic mice. Cancer Res 1997;57:1294-1300 (Pubitemid 27152554)
34. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994;54:800-804 (Pubitemid 24068340)
35. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996;93:2930-2935 (Pubitemid 26114341)
36. Lu ZH, Wright JD, Belt B, Cardiff RD, Arbeit JM. Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. Am J Pathol 2007;171:667-681 (Pubitemid 47344698)
37. Shai A, Pitot HC, F. LP. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008;68:2622-2631
38. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 2003;63:8173-8180 (Pubitemid 37549465)
39. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-275
40. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40. (Pubitemid 43108832)